Enterprise Value
14.87B
Cash
858.4M
Avg Qtr Burn
N/A
Short % of Float
0.14%
Insider Ownership
0.41%
Institutional Own.
14.91%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ORPATHYS (Savolitinib) (C-MET inhibitor) Details Non-small cell lung carcinoma, Cancer, Colorectal cancer , Renal cell carcinoma, Gastric cancer | Approved Quarterly sales | |
ELUNATE (Fruquintinib) (VEGFR 1/2/3) Details Colorectal cancer , Metastatic colorectal cancer, Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Quarterly sales | |
ELUNATE (Fruquintinib) + paclitaxel Details Solid tumor/s, Cancer, Gastroesophageal adenocarcinomas, Gastric cancer | NDA Acceptance for review | |
Sovleplenib (HMPL-523) (Syk inhibitor) Details Primary immune thrombocytopenia | NDA Submission | |
ORPATHYS (Savolitinib) (C-MET inhibitor) Details Renal cell carcinoma, Cancer, Gastric cancer | Phase 3 Data readout | |
ORPATHYS (Savolitinib) + TAGRISSO Details Non-small cell lung carcinoma, Cancer | Phase 3 Interim Update | |
SULANDA (Surufatinib) Details Solid tumor/s, Pancreatic cancer, Neuroendocrine tumor, Cholangiocarcinoma, Cancer | Phase 3 Update | |
Tazemetostat Details Follicular lymphoma | Phase 2 Data readout | |
Amdizalisib (HMPL-689) (PI3K) Details Non-Hodgkin lymphoma | Phase 2 Data readout | |
HMPL-453 (FGFR 1/2/3) Details Mesothelioma, Intrahepatic cholangiocarcinoma , Cancer | Phase 2 Update | |
ELUNATE (Fruquintinib) + Sintilimab Details Solid tumor/s, Cancer, Triple-negative breast cancer , Endometrial cancer, Renal cell carcinoma | Phase 1/2 Data readout | |
Sovleplenib (HMPL-523) (Syk inhibitor) Details Warm autoimmune hemolytic anemia | Phase 1/2 Update | |
Sovleplenib (HMPL-523) (Syk inhibitor) Details Non-Hodgkin lymphoma | Phase 1/2 Initiation | |
HMPL-306 Details Blood cancer, Hematologic malignancies | Failed Discontinued |